Lately, more selective drugs, such as larotrectinib (anti-TRK), entrectinib (anti-ALK, ROS1, and TRK), selpercatinib, and pralsetinib (both anti-RET), have proved significantly improved benefit–risk balance in clinical trials with kinase fusion-positive thyroid carcinoma patients [145]. The gene discussed is NTRK1; the disease is thyroid gland carcinoma.